India, Nov. 11 -- Hansa Biopharma AB (HNSA.ST), a commercial-stage biopharmaceutical company, on Wednesday announced financial results for the third quarter ending September 30, 2026, and reported a wider loss despite higher revenues due to increased expenses.
The company develops immunomodulatory therapies for the treatment of immune disorders such as Guillain-Barre Syndrome (GBS). By use of Hansa's proprietary IgG technology platform, an antibody-cleaving enzyme therapy called Imlifidase (market name Idefirix) was designed to facilitate kidney transplants in highly sensitized patients. Additionally, the company is advancing HNSA-5487 for treating GBS under the same platform.
Q3 Financial Results:
Net loss for the third quarter came to ...